Table 1.

Baseline characteristics of patients with nephrotic syndrome and controls

Baseline CharacteristicsCases (n=2620)Controls (n=10,454)
Age, yr, mean±SD58±1757±17
 18–64 yr old, n (%)1579 (60)6316 (60)
 >64 yr old, n (%)1041 (40)4138 (40)
Women, n (%)1432 (55)5714 (55)
Body mass index, kg/m2, mean±SD28.0±6.327.0±5.4
 Underweight, <18.5 kg/m2, n (%)57 (2)229 (2)
 Normal weight, 18.5–24.9 kg/m2, n (%)783 (30)3278 (31)
 Overweight, 25.0–29.9 kg/m2, n (%)808 (31)3453 (33)
 Obesity, >30 kg/m2, n (%)753 (29)2207 (21)
 Unknown, n (%)219 (8)1287 (12)
Comorbidities associated with nephrotic syndrome, n (%)
 Diabetes mellitus629 (24)740 (7)
 SLE120 (5)7 (0)
 Rheumatoid arthritis36 (1)82 (1)
 Amyloidosis23 (1)1 (0)
 Leukemia13 (1)16 (0)
Comorbidities associated with kidney toxicity, n (%)
 Hypertension1190 (45)2655(25)
 CKD474 (18)188 (2)
 Heart failure204 (8)219 (2)
 Chronic liver disease42 (2)70 (1)
Comedications within 6 mo before the index date, n (%)
 Cardiovascular drugsa1843 (70)3392 (32)
 Systemic corticosteroids413 (16)316 (3)
 Antibioticsb98 (4)93 (1)
 Chemotherapeutic agents83 (3)87 (1)
Smoking status, n (%)
 Current553 (21)2272 (22)
 Ever947 (36)3112 (30)
 Never1042 (40)4545 (43)
 Unknown78 (3)525 (5)
Alcohol abuse, n (%)126 (5)412 (4)
  • a Angiotensin-converting enzymes inhibitors, angiotensin II antagonists, β-blockers, diuretics, calcium channel blockers, and statins.

  • b Aminoglycosides, sulfamethoxazole and trimethoprim, vancomycin, and ciprofloxacin.